|
Normoalbuminuric type 2 diabetes
(n=50) |
Micro-albuminuric
type 2 diabetes
(n=50) |
Control (n=50) |
ANOVA |
Tukey’s test |
f |
p |
P1 |
P2 |
P3 |
Fasting blood glucse (mg/dl) |
214.5 ± 54.7 |
246.5 ± 65.8 |
78.1 ± 7.8 |
121.1 |
<0.001* |
0.003* |
<0.001* |
<0.001* |
2-h PP blood glucose (mg/dl) |
280.1 ± 63.7 |
361.3 ± 54.2 |
95.1 ± 15.9 |
228.4 |
<0.001* |
<0.001* |
<0.001* |
<0.001* |
HDL (mg/dl) |
48.1 ± 8.9 |
39.6 ± 6.2 |
48.9 ± 5.1 |
23.5 |
<0.001* |
<0.001* |
0.6 |
<0.001* |
TAG (mg/dl) |
116.5 ± 42.7 |
139.9 ± 36.8 |
96.7 ± 15.1 |
5.2 |
0.007 |
0.02* |
0.9 |
0.01* |
TC (mg/dl) |
230.4 ± 61.3 |
271.5 ± 51.6 |
171.8 ± 32.7 |
18.8 |
<0.001* |
0.009* |
0.01* |
<0.001* |
LDL (mg/dl) |
161.1 ± 63.7 |
204.5 ± 49.3 |
103.9 ± 28.7 |
21.1 |
<0.001* |
<0.001* |
0.26 |
<0.001* |
Fasting insulin (μIU/ml) |
8.6 ± 5.6 |
13.3 ± 4.9 |
4.1 ± 1.5 |
21.6 |
<0.001* |
<0.001* |
<0.001* |
<0.001* |
HOMA-IR |
4.7 ± 3.8 |
7.9 ± 4.5 |
1.1 ± 0.3 |
23.8 |
<0.001* |
0.001* |
<0.001* |
<0.001* |
Urinary Albumin/Creatinine ratio (UACR , mg/g) |
16.9 ± 9.5 |
74.6 ± 33.1 |
18.1 ± 6.3 |
109.3 |
<0.001* |
<0.001* |
0.001* |
<0.001* |
Urea (mg %) |
33.5 ± 9.1 |
73.4 ± 18.7 |
25.7 ± 6.8 |
135.3 |
<0.001* |
<0.001* |
0.22 |
<0.001* |
Serum creatinine (mg/dl) |
0.79 ± 0.3 |
0.94 ± 0.7 |
0.7 ± 0.1 |
5.5 |
0.001* |
<0.001* |
0.52 |
<0.001* |
estimated GFR (eGFR ,ml/min per 1.73m2 ) |
95.6 ± 29.3 |
71.5 ± 25.3 |
94.4 ± 17.3 |
4.8 |
0.011* |
0.02* |
0.98 |
0.02* |
sRAGE, pg/mL |
3275 ± 270 |
4859 ± 317 |
1562 ± 386 |
748.7 |
<0.001* |
<0.001* |
<0.001* |
<0.001* |
Pentosidinepg/mL |
273 ± 85 |
298 ± 26 |
257 ± 43 |
7.08 |
0.002* |
0.943 |
0.003* |
0.008* |
AOPPs (μmol/l) |
189 ± 5.1 |
203.1 ± 7.3 |
125.83 ± 4.05 |
1409.7 |
<0.001* |
<0.001* |
<0.001* |
<0.001* |
Data presented as means ± SD. P was calculated by one way ANOVA test followed by Tukey’s post-hoc test. P was considered significant at <0.05.; *Significant; P1 comparison between group I and II; P2 comparison between group I and III; P3 comparison between group II and III. |